Clinical Outcomes of Molecular Tumor Boards: A Systematic Review

Kara L. Larson; Bin Huang; Heidi L. Weiss; Pam Hull; Philip M. Westgate; Rachel W. Miller; Susanne M. Arnold; Jill M. Kolesar

doi:10.1200/PO.20.00495

Back

Clinical Outcomes of Molecular Tumor Boards: A Systematic Review

Journal article

Open access

Peer reviewed

Clinical Outcomes of Molecular Tumor Boards: A Systematic Review

Kara L. Larson, Bin Huang, Heidi L. Weiss, Pam Hull, Philip M. Westgate, Rachel W. Miller, Susanne M. Arnold and Jill M. Kolesar

JCO precision oncology, Vol.5(5), pp.1122-1132

07/01/2021

DOI: 10.1200/PO.20.00495

PMCID: PMC8277300

PMID: 34632252

Files and links (1)

url

https://doi.org/10.1200/PO.20.00495View

Published (Version of record) Open Access

Abstract

PURPOSE We conducted this systematic review to evaluate the clinical outcomes associated with molecular tumor board (MTB) review in patients with cancer. METHODS A systematic search of PubMed was performed to identify studies reporting clinical outcomes in patients with cancer who were reviewed by an MTB. To be included, studies had to report clinical outcomes, including clinical benefit, response, progression-free survival, or overall survival. Two reviewers independently selected studies and assessed quality with the Quality Assessment Tool for Before-After (Pre-Post) Studies with No Control Group or the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies depending on the type of study being reviewed. RESULTS Fourteen studies were included with a total of 3,328 patients with cancer. All studies included patients without standard-of-care treatment options and usually with multiple prior lines of therapy. In studies reporting response rates, patients receiving MTB-recommended therapy had overall response rates ranging from 0% to 67%. In the only trial powered on clinical outcome and including a control group, the group receiving MTB-recommended therapy had significantly improved rate of progression-free survival compared with those receiving conventional therapy. CONCLUSION Although data quality is limited by a lack of prospective randomized controlled trials, MTBs appear to improve clinical outcomes for patients with cancer. Future research should concentrate on prospective trials and standardization of approach and outcomes.

Details

Title: Subtitle: Clinical Outcomes of Molecular Tumor Boards: A Systematic Review
Creators: Kara L. Larson - University of Kentucky
Bin Huang - Markey Cancer Center
Heidi L. Weiss - University of Kentucky
Pam Hull - University of Kentucky
Philip M. Westgate - University of Kentucky
Rachel W. Miller - Markey Cancer Center
Susanne M. Arnold - University of Kentucky
Jill M. Kolesar - University of Kentucky
Resource Type: Journal article
Publication Details: JCO precision oncology, Vol.5(5), pp.1122-1132
DOI: 10.1200/PO.20.00495
PMID: 34632252
PMCID: PMC8277300
NLM abbreviation: JCO Precis Oncol
ISSN: 2473-4284
eISSN: 2473-4284
Language: English
Date published: 07/01/2021
Academic Unit: Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
Record Identifier: 9984696554102771

Metrics

4 Record Views

82 Times Cited - Web of Science